Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program

Charles G Peterfy, Vibeke Strand, Alan Friedman, Stephen Hall, Eduardo Mysler, Patrick Durez, Xenofon Baraliakos, Jeffrey V Enejosa, Tim Shaw, Yihan Li, Su Chen, In-Ho Song, Charles G Peterfy, Vibeke Strand, Alan Friedman, Stephen Hall, Eduardo Mysler, Patrick Durez, Xenofon Baraliakos, Jeffrey V Enejosa, Tim Shaw, Yihan Li, Su Chen, In-Ho Song

Abstract

Objectives: To evaluate the inhibition of progression of structural joint damage through week 48 in patients with moderately to severely active RA receiving upadacitinib as monotherapy or in combination with MTX.

Methods: Radiographic progression was assessed in two phase 3 randomized controlled trials. MTX-naïve patients were randomized to upadacitinib 15 or 30 mg once daily or MTX monotherapy (SELECT-EARLY, n = 945), while MTX inadequate responders (IRs) were randomized to upadacitinib 15 mg once daily or adalimumab 40 mg every other week or placebo added to background MTX (SELECT-COMPARE, n = 1629). The mean changes from baseline in modified total Sharp score (mTSS), joint space narrowing and erosion scores were determined. Data were analysed both by linear extrapolation for missing data imputation and treatment switching and as observed.

Results: In patients naïve or with limited exposure to MTX (SELECT-EARLY), mean changes from baseline to week 48 in mTSS were 0.03 for upadacitinib 15 mg, 0.14 for upadacitinib 30 mg and 1.00 for MTX based on linear extrapolation (P < 0.001 for both upadacitinib doses vs MTX). Among patients with an inadequate response to MTX (SELECT-COMPARE), the mean change from baseline in mTSS was significantly reduced in the upadacitinib 15 mg plus MTX group vs placebo plus MTX (0.28 vs 1.73; P < 0.001). The mean change from baseline in the adalimumab plus MTX group was 0.39.

Conclusion: Upadacitinib monotherapy or in combination with background MTX was effective in inhibiting the progression of structural joint damage through week 48 in MTX-naïve and MTX-IR patients with RA.

Trial registration: ClinicalTrials.gov (https://ichgcp.net/clinical-trials-registry/NCT02706873" title="See in ClinicalTrials.gov">NCT02706873 and NCT02629159.

Keywords: DMARDs; biological therapies; outcome measures; radiology; rheumatoid arthritis.

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Figures

Fig . 1
Fig. 1
Change from baseline in mTSS in the (A) LE and (B) as-observed analyses over 1 year In SELECT-COMPARE, at week 26 (6-month visit), patients receiving placebo were switched to upadacitinib. The month 6 analysis was conducted at week 24 in SELECT-EARLY and week 26 in SELECT-COMPARE; the year 1 analysis was conducted at week 48 in both studies. eow, every other week; PBO, placebo; UPA, upadacitinib. ***P < 0.001 upadacitinib vs MTX or placebo. ###P < 0.001 and #P < 0.05 adalimumab vs placebo.
Fig . 2
Fig. 2
Percentage of non-progressors at (A) 6 months and (B) 1 year LE and as-observed analyses. Non-progressor defined as a patient with a change from baseline in mTSS ≤0. In SELECT-COMPARE, at week 26 (6-month visit), patients receiving placebo were switched to upadacitinib. The month 6 analysis was conducted at week 24 in SELECT-EARLY and week 26 in SELECT-COMPARE; the year 1 analysis was conducted at week 48 in both studies. eow, every other week. ***P < 0.001 upadacitinib vs MTX or placebo; ###P < 0.001 adalimumab vs placebo.
Fig . 3
Fig. 3
Cumulative probability plots of mean change in mTSS in the (A) LE and (B) as-observed analyses The 1-year analysis. In SELECT-COMPARE, at week 26 (6-month visit), patients receiving placebo were switched to upadacitinib. eow: every other week.
Fig . 4
Fig. 4
Change from baseline in (A, B) joint-space narrowing and (C, D) erosion scores The (A and C) LE and (B and D) as-observed analyses. In SELECT-COMPARE, at week 26 (6-month visit), patients receiving placebo were switched to upadacitinib. The month 6 analysis was conducted at week 24 in SELECT-EARLY and week 26 in SELECT-COMPARE; the year 1 analysis was conducted at week 48 in both studies. eow: every other week; ES: erosion score; JSN: joint-space narrowing score; PBO: placebo; UPA: upadacitinib. ***P < 0.001, **P < 0.01, *P < 0.05 upadacitinib vs MTX or placebo. ###P < 0.001 and ##P < 0.01 adalimumab vs placebo.
Fig . 5
Fig. 5
Change in (A) mTSS, (B) joint-space narrowing, (C) erosion score and (D) percentage of non-progressors Analyses among non-switchers in the SELECT-EARLY and SELECT COMPARE (as-observed analysis). SELECT-EARLY at 6 months: MTX, n = 232; upadacitinib 15 mg, n = 263; upadacitinib 30 mg, n = 266; and at 1 year: MTX, n = 215; upadacitinib 15 mg, n = 249; upadacitinib 30 mg, n = 255. SELECT-COMPARE at 6 months: upadacitinib 15 mg, n = 348; adalimumab 40 mg, n = 136; and at 1 year: upadacitinib 15 mg, n = 342; adalimumab 40 mg, n = 132. Non-switchers were patients who remained on randomized therapy. eow: every other week; ES: erosion score; JSN: joint-space narrowing score; PBO: placebo; UPA: upadacitinib.

References

    1. Wolfe F, Sharp JT.. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum 1998;41:1571–82.
    1. Sokka T. Long-term outcomes of rheumatoid arthritis. Curr Opin Rheumatol 2009;21:284–90.
    1. Smolen JS, Landewe RBM, Bijlsma JWJ. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79:685–99.
    1. Combe B, Lula S, Boone C, Durez P.. Effects of biologic disease-modifying anti-rheumatic drugs on the radiographic progression of rheumatoid arthritis: a systematic literature review. Clin Exp Rheumatol 2018;36:658–67.
    1. Murray E, Ellis A, Butylkova Y. et al. Systematic review and network meta-analysis: effect of biologics on radiographic progression in rheumatoid arthritis. J Comp Eff Res 2018;7:959–74.
    1. Parmentier JM, Voss J, Graff C. et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol 2018;2:23.
    1. RINVOQ (upadacitinib). Full prescribing information. North Chicago, IL: AbbVie, 2019.
    1. RINVOQ (upadacitinib). Summary of product characteristics. Weisbaden, Germany: AbbVie Deutschland, 2019.
    1. Fleischmann R, Pangan AL, Song IH. et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol 2019;71:1788–800.
    1. Vollenhoven R, Takeuchi T, Pangan AL. et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately to severely active rheumatoid arthritis (SELECT-EARLY): a randomized, double-blind, active-comparator, multi-center, multi-country trial. Arthritis Rheumatol 2020;72:1607–20.
    1. Fleischmann RM, Genovese MC, Enejosa JV. et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis 2019;78:1454–62.
    1. van der Heijde DM, van Leeuwen MA, van Riel PL. et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35:26–34.
    1. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999;26:743–5.
    1. Bruynesteyn K, Boers M, Kostense P, van der Linden S, van der Heijde D.. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis 2005;64:179–82.
    1. Landewe R, van Tubergen A.. Clinical tools to assess and monitor spondyloarthritis. Curr Rheumatol Rep 2015;17:47.
    1. van Nies JA, Krabben A, Schoones JW. et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 2014;73:861–70.
    1. Kyburz D, Gabay C, Michel BA, Finckh A; for the physicians of the SCQM-RA. The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study. Rheumatology (Oxford) 2011;50:1106–10.
    1. van der Heijde D, Dougados M, Chen YC. et al. Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open 2018;4:e000662.
    1. van der Heijde D, Schiff M, Tanaka Y. et al. Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. RMD Open 2019;5:e000898.
    1. Westhovens R, Rigby W, van der Heijde D. et al. SAT0158 Efficacy and safety of filgotinib in methotrexate-naïve patients with rheumatoid arthritis: FINCH 3 52-week results. Ann Rheum Dis 2020;79:1019–20.
    1. Combe B, Kivitz A, Tanaka Y. et al. Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH1 primary outcome results. Arthritis Rheumatol 2019;71(Suppl 10):abstract 506.
    1. Fleischmann R, Schiff M, van der Heijde D. et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 2017;69:506–17.
    1. van der Heijde D, Tanaka Y, Fleischmann R. et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013;65:559–70.
    1. Lee EB, Fleischmann R, Hall S. et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370:2377–86.
    1. Westhovens R, Taylor PC, Alten R. et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis 2017;76:998–1008.
    1. Keystone EC, Kavanaugh AF, Sharp JT. et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400–11.
    1. Breedveld FC, Weisman MH, Kavanaugh AF. et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26–37.
    1. Kavanaugh A, Fleischmann RM, Emery P. et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64–71.
    1. Markusse IM, Landewe R, Wolterbeek R. et al. Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritis. Rheumatology (Oxford) 2016;55:1295–300.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj